Abstract
This is a review of the epidemiology and management of infectious complications in contemporary management of chronic leukemias. Patients with chronic leukemias typically are affected by nuisance infections due to the underlying hematologic condition, particularly hypogammaglobulinemia in CLL patients. With active treatment, particularly those agents that cause defects in cell-mediated immunity, the incidence of opportunistic infections increases although endogenous bacterial, mycobacterial, and fungal infections also occur. Exogenous treatment with immunoglobulin and antimicrobial prophylaxis, particularly anti-Pneumocystis prophylaxis, may be indicated in select patients. Routine vaccinations should be maintained in these patients and vaccination early in the course of treatment may result in improve protection.
Keywords: Chronic myelogenous leukemia (CML), chronic granulocytic leukemia (CGL), chronic lymphoid leukemia (CLL), hypogammaglobulinemia, opportunistic infection, Pneumocystis, anti-Pneumocystis prophylaxis, B-cell chronic, white blood cells, alkylating, prednisone, rituximab, alemtuzumab, hairy cell leukemia, neutropenia, monocytopenia, T-cell dysfunction, Sweet's syndrome, chronic myelogenous, myeloid, stem cells, chronic granulocytic leukemia, Allogeneic hematopoietic stem cell, mycobacteria, Aspergillus, legionellosis, salmonellosis, toxoplasmosis, listeriosis, Listeria, Pas-teurella multocida tracheobronchitis, Toxoplasma cyst, Cryptococcus, Chlamydophila psittaci
Infectious Disorders - Drug Targets
Title: Epidemiology and Management of Infectious Complications in Contemporary Management of Chronic Leukemias
Volume: 11 Issue: 1
Author(s): Jo-Anne H. Young
Affiliation:
Keywords: Chronic myelogenous leukemia (CML), chronic granulocytic leukemia (CGL), chronic lymphoid leukemia (CLL), hypogammaglobulinemia, opportunistic infection, Pneumocystis, anti-Pneumocystis prophylaxis, B-cell chronic, white blood cells, alkylating, prednisone, rituximab, alemtuzumab, hairy cell leukemia, neutropenia, monocytopenia, T-cell dysfunction, Sweet's syndrome, chronic myelogenous, myeloid, stem cells, chronic granulocytic leukemia, Allogeneic hematopoietic stem cell, mycobacteria, Aspergillus, legionellosis, salmonellosis, toxoplasmosis, listeriosis, Listeria, Pas-teurella multocida tracheobronchitis, Toxoplasma cyst, Cryptococcus, Chlamydophila psittaci
Abstract: This is a review of the epidemiology and management of infectious complications in contemporary management of chronic leukemias. Patients with chronic leukemias typically are affected by nuisance infections due to the underlying hematologic condition, particularly hypogammaglobulinemia in CLL patients. With active treatment, particularly those agents that cause defects in cell-mediated immunity, the incidence of opportunistic infections increases although endogenous bacterial, mycobacterial, and fungal infections also occur. Exogenous treatment with immunoglobulin and antimicrobial prophylaxis, particularly anti-Pneumocystis prophylaxis, may be indicated in select patients. Routine vaccinations should be maintained in these patients and vaccination early in the course of treatment may result in improve protection.
Export Options
About this article
Cite this article as:
H. Young Jo-Anne, Epidemiology and Management of Infectious Complications in Contemporary Management of Chronic Leukemias, Infectious Disorders - Drug Targets 2011; 11(1) . https://dx.doi.org/10.2174/187152611794407755
DOI https://dx.doi.org/10.2174/187152611794407755 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
The Role of Endothelial Dysfunction in Aortic Aneurysms
Current Pharmaceutical Design Cardioembolic Stroke: Clinical Features, Specific Cardiac Disorders and Prognosis
Current Cardiology Reviews Urokinase-a Very Popular Cardiovascular Agent
Recent Patents on Cardiovascular Drug Discovery The Role of Oxidative Stress in Smoking-Related Diseases
Mini-Reviews in Organic Chemistry Forceps: Still an Option?
Current Women`s Health Reviews Delayed Cerebral Ischemia after Subarachnoid Hemorrhage: From Vascular Spasm to Cortical Spreading Depolarizations
Current Neurovascular Research Pathophysiology of IgG4-Related Disease
Current Immunology Reviews (Discontinued) c-Myc and Downstream Targets in the Pathogenesis and Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery The Promise of Mesenchymal Stem Cells Therapy for Acute Respiratory Distress Syndrome Caused by COVID-19
Current Stem Cell Research & Therapy Spectrophotometric Quantification of Bilirubin in Hemorrhagic Spinal Fluid using an Innovative Algorithm
Medicinal Chemistry MiR-147: Functions and Implications in Inflammation and Diseases
MicroRNA Intravenous Antihypertensives within Cardiovascular-Based Continuity of Care
Current Vascular Pharmacology Contribution and Value of Biomarkers in Acute Aortic Syndromes
Current Pharmaceutical Biotechnology Congenital Heart Disease: The Crossroads of Genetics, Epigenetics and Environment
Current Genomics Hyaluronan: The Jekyll and Hyde Molecule
Inflammation & Allergy - Drug Targets (Discontinued) Gender Medicine and Pharmacoeconomics: A Narrative Review of the International Literature of the Last 5 Years. A Revision of Evidences about the Relationship Between Gender and Economic Consumption in Health
Current Pharmaceutical Design Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets
Current Genomics Vitamin D Metabolites and/or Analogs: Which D for Which Patient?
Current Vascular Pharmacology Remodeling of the Myocardium and Potential Targets in the Collagen Degradation and Synthesis Pathways
Current Drug Targets - Cardiovascular & Hematological Disorders Lessons from the REACH Registry in Europe
Current Vascular Pharmacology